Additionally, The Board of Regents of the University of Texas System, United States, Regeneron Pharmaceuticals, Inc. and other organizations or companies have similarly conducted research on siRNA drugs targeting CIDEB, suggesting that CIDEB is of interest as a NASH‐associated disease target has attracted much attention.272, 273. Here, CIDEB is linked to metabolic dysfunction-associated steatohepatitis.